ReviewFrontiers in bioengineering and biotechnology2026
Bioprinting functional fat - adipocytes as the next frontier in tissue engineering, regenerative medicine, and cultivated meat.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose tissue is a vital component in both regenerative medicine and cultivated meat, yet the selection of the cellular starting material remains an underexplored determinant of adipose construct performance in bioprinting. This mini-review explores next-generation adipose tissue engineering, emphasizing bioprinting functional fat with adipocytes at the intersection of these two fields. While current adipose bioprinting strategies predominantly rely on adipose-derived stem or stromal cells for their expandability and manufacturability, mature adipocytes (ACs) and microfat emerge as alternative cell sources with distinct advantages in functional fidelity, metabolic relevance, and immediate tissue-like behavior. However, these approaches impose fundamentally different biological and engineering constraints that directly influence biofabrication strategy, biomaterial design, and translational potential. This mini review offers a structured comparison of mature adipocyte-, progenitor-, and microtissue-based strategies, highlighting features that influence biofabrication and applicability. Scalability is identified as a major bottleneck in translation, with a focus on process robustness, batch-to-batch reproducibility, and manufacturing concepts relevant to preclinical test systems, clinical applications, and large-scale cultivated meat (CM) production. By proposing a cell-source-guided framework for adipose bioprinting, this mini review aims to provide a practical decision-making perspective for developing next-generation adipose constructs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.